ATHA Athira Pharma Inc Total Business Assets

ATHA (Athira) - company brandmark

Athira Pharma, Inc. (ATHA) specializes in developing innovative therapies for nervous system diseases. The visualization of the total asset market value, which stands at 58.14, reflects the company's financial condition, which depends on the outcomes of Alzheimer's drug trials and capital volume. The business potential relies on unique molecules that restore neural connections via the HGF/MET pathway, providing significant pricing power. Management is currently revising the development vector following the failure of the primary drug.

Cumulative Company Assets: Athira Pharma, Inc. (ATHA) for 07/04/2022 - 01/12/2026

Analytical breakdowns and data insights for company Athira (ATHA)

- market value and analyst target forecast:
Stock Price athira.com|ATHA - Price Target Chart
- market capitalization data:
Market Capitalization Athira Pharma Corp|ATHA - Enterprise Value
- book capitalization information:
Net Asset Value per Share Athira Pharma|ATHA - Company Net Assets|Market Capitalization to Book Value Ratio athira.com|ATHA - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Athira Pharma, Inc.|ATHA - Long-Term Debt to Equity|Current Liabilities to Capital Athira Pharma Corp|ATHA - Company Aggregate Debts|Debts to Book Capitalization Athira Pharma Corp|ATHA - Company Long-Term Liabilities|Amount of Current Liabilities Athira Pharma|Intermediate Coverage Ratio athira.com
- company profitability and valuation multiples indicators:
ATHA - Net Profit
Fundamental valuation:Athira Pharma, Inc.
Manufactured products of Athira Pharma

To objectively assess the stability of Athira Pharma, Inc. (ATHA), investors must analyze the volume of resources, calculated inversely via return on assets (ROA), to track capital dynamics between reports. The trajectory of total assets (via ROA) demonstrates the effectiveness of cost restructuring and the company's ability to fund the development of second-generation molecules amid a strategic transition following the failures of its flagship drug.

Key competitors

biogen.com (BIIB) - Company Total Assets|Aggregate Company Assets Neurocrine Biosciences, Inc.|Total Business Assets RGC (Regencell Bioscience Ltd)|Company Total Assets AXSM|ACAD - Company Assets|Xenon Pharmaceuticals - Cumulative Company Assets|Company Total Assets vikingtherapeutics.com VKTX|SUPN - Aggregate Company Assets|Aggregate Asset Value CPRX (Catalyst Pharma)|Denali Therapeutics Inc (DNLI) - Aggregate Company Assets|Company Assets Harmony Corp (HRMY)|BHVN (Biohaven Ltd.) - Company Total Assets|Company Total Assets amylyx.com|Cumulative Company Assets TRVI (Trevi Therapeutics, Inc.)|Aggregate Business Assets PRAX|Company Total Assets AVXL (Anavex Corp)|Aggregate Asset Value CBLL|Prothena Corporation plc - Company Total Assets|Company Total Asset Base Alector, Inc. ALEC|Annexon (ANNX) - Aggregate Company Assets|Omeros - Aggregate Asset Value|NGNE (Neurogene Corp) - Company Total Assets|Company Total Assets AC Immune Inc|Cumulative Company Assets VYGR (Voyager Therapeutics)|NMRA (neumoratx.com) - Aggregate Asset Value|Aggregate Company Assets Scilex SCLX|TVGN (Tevogen Bio Holdings Inc.) - Total Asset Value of Company|Alpha Cognition Corp - Company Total Assets|Aggregate Asset Value CGTX (Cognition Therapeutics Inc.)|IKT: Company Total Assets|cassavasciences.com (SAVA) - Company Total Assets|Aggregate Company Assets Assertio Holdings|COYA: Aggregate Asset Value|Aggregate Company Assets Vistagen Therapeutics (VTGN)|Cumulative Company Assets ovidrx.com OVID|Company Total Assets ABOS (Acumen Pharmaceuticals)|Company Total Assets cervomed.com CRVO|ATHE: Cumulative Company Assets|Aggregate Asset Value CLNN (Clene Inc.)|PEPG: Company Total Assets|JUNS - Company Total Asset Base|Aggregate Company Assets Relmada Therapeutics|Total Business Assets ANVS (annovisbio.com)|Company Total Assets GRCE|Cumulative Company Assets Firefly Neuroscience, Inc. AIFF|Klotho Neurosciences - Cumulative Company Assets|Company Total Asset Base NeuroSense Therapeutics Ltd (NRSN)|Reviva Pharmaceuticals - Company Total Assets|MTVA - Company Total Assets|NRXS (NeurAxis) - Cumulative Company Assets|HSDT: Aggregate Business Assets|PASG (Passage Bio Inc.) - Company Total Assets|NEUP: Aggregate Asset Value|Company Total Assets NERV|Company Total Assets addextherapeutics.com (ADXN)|Aggregate Company Assets Alzamend Neuro ALZN|CYCN: Total Business Assets|Protagenic - Company Total Assets|Company Assets Pasithea Therapeutics|CRGT (cortigent.com) - Cumulative Company Assets|avenuetx.com (ATXI) - Company Total Assets|Aggregate Company Assets BrainStorm Cell Therapeutics|CARA: Aggregate Asset Value|Aggregate Company Assets Chromocell Therapeutics Corporation (CHRO)|ELYM - Company Assets|Company Total Assets ITCI (Intra-Cellular Therapies, Inc.)|Company Total Assets longboardpharma.com LBPH|MRNS: Cumulative Company Assets|NKGen Biotech Inc - Aggregate Business Assets|NRBO: Company Total Assets|Sage Therapeutics Inc - Aggregate Asset Value|SNPX (Synaptogenix, Inc.) - Company Total Assets|trevena.com (TRVN) - Company Total Asset Base|Aggregate Company Assets Vigil Neuroscience (VIGL)|WENA (anewmeds.com) - Aggregate Asset Value|Company Total Assets CERE (Cerevel)